英飞特：拟对外投资及上市公司实控人对本次投资承担或有回购义务

Core Viewpoint - Infinet (300582.SZ) has approved a capital increase and equity transfer agreement involving its wholly-owned subsidiary, Hangzhou Infinet Equity Investment Co., Ltd., and Qinghai Chunwarm Biotechnology Co., Ltd., indicating a strategic investment move in the biotechnology sector [1] Group 1: Investment Details - Infinet Equity Investment plans to invest CNY 13.44 million in Chunwarm Biotechnology, with CNY 1.344 million allocated to the new registered capital and the remainder as capital premium [1] - The company will also acquire all registered capital of Blincao Biotechnology for CNY 1.56 million, which is part of the overall transaction [1] - Upon completion of the transaction, Infinet Equity Investment will hold 2.62% direct equity in Chunwarm Biotechnology and an indirect 3.04% through Blincao Biotechnology [1] Group 2: Profit Guarantees - The controlling shareholder, GUICHAOHUA, has committed to a profit guarantee, allowing Infinet Equity Investment to demand a buyback of its shares if Chunwarm Biotechnology's net profit is negative over 2026 and 2027, or if the combined net profit for 2026, 2027, and 2028 does not reach CNY 60 million [2] - This transaction is classified as a related party transaction due to the involvement of the controlling shareholder [2]